Condiciones de salud que romero puede ayudar a apoyar.
Rosemary (Rosmarinus officinalis) contains the phenolic diterpenes carnosic acid and carnosol, and the polyphenol rosmarinic acid, all of which are well-documented antioxidants in in vitro and animal models. These compounds scavenge reactive oxygen species (ROS), inhibit lipid peroxidation, and upregulate endogenous antioxidant enzyme systems via the Nrf2/ARE signaling pathway. Clinical human trials remain limited, though a randomized placebo-controlled trial in type 2 diabetes patients (12 weeks) is underway measuring oxidative stress biomarkers such as MDA, SOD, and GSH. Current evidence is primarily preclinical, making the mechanistic basis strong but human clinical confirmation still emerging.
Multiple human clinical trials show rosemary reduces anxiety scores in healthy students and patients with major depressive disorder. A randomized, double-blind, placebo-controlled crossover trial also found that rosemary extract significantly improved trait anxiety on the STAI and reduced state anxiety after a single dose. Evidence points to rosmarinic acid modulating oxidative stress and inflammatory pathways involved in anxiety.
A 2025 double-blind RCT demonstrated that 12 weeks of oral rosemary leaf powder (4 g/day) in 72 rheumatoid arthritis patients significantly reduced disease activity scores, joint counts, pain scores, CRP, and ESR. An earlier pilot trial with a rosemary-containing combination also found significant VAS pain reductions in osteoarthritis and rheumatoid arthritis patients.
A pilot clinical trial described as the first human investigation of rosemary infusion's antihypertensive effects found preliminary evidence of blood pressure reduction. Traditional use for both low and high blood pressure is long-established. Human clinical data specifically for rosemary monotherapy in hypertension remains limited.
Human clinical trials show rosemary supplementation can reduce fasting blood glucose and HbA1c, particularly in diabetic patients. Mechanistic studies identify AMPK and PPAR pathway activation by rosemary extract as key drivers of improved glucose metabolism. Evidence is early-stage with some trials showing only modest benefit independent of lifestyle changes.
Rosemary has been studied for cognitive clarity and mental fatigue in human trials. A study in COPD patients found rosemary hydroalcoholic extract improved cognitive function and reduced fatigue-associated cognitive impairment. Traditional medicine classifies rosemary as a tonic herb for physical and mental fatigue.
Rosemary's anti-inflammatory bioactives—rosmarinic acid, carnosic acid, carnosol, and ursolic acid—inhibit NF-κB, COX-2, TNF-α, and IL-6 pathways, well established in preclinical models. A 2025 double-blind RCT in rheumatoid arthritis patients confirmed significant reductions in CRP and ESR after 12 weeks of rosemary leaf powder, providing direct human evidence of systemic anti-inflammatory effects.
Rosemary—both topically and orally—has demonstrated analgesic effects in human clinical trials, including reductions in musculoskeletal pain in hemodialysis patients and joint pain in arthritis patients. Its antinociceptive properties are attributed to COX-2 inhibition, lipoxygenase inhibition, and modulation of pain-related inflammatory mediators.
Rosemary and its bioactives rosmarinic acid and carnosic acid have demonstrated neuroprotective effects in preclinical models of Alzheimer's and Parkinson's disease. Human studies show rosemary water and aromatherapy improve cognitive function markers in elderly adults. Carnosic acid crosses the blood-brain barrier and activates NRF2/Nrf2 pathways that protect against neurodegeneration.
A 2024 Scientific Reports study (PMC) showed that a standardized rosemary-neem combined extract had superior antifungal activity against Malassezia furfur compared to ketoconazole, with confirmed anti-inflammatory activity and scalp penetration. A PubMed review explicitly names rosemary oil among essential oils with recognized anti-dandruff potential. Rosemary has traditional use in Mediterranean hair care for dandruff control.
A randomized, double-blind, placebo-controlled trial demonstrated that rosemary capsules used adjunctively with SSRIs significantly reduced Beck Depression Inventory scores in patients with major depressive disorder. Rosemary tea also altered BDNF—a key depression biomarker—in healthy volunteers. Proposed mechanisms involve the monoaminergic system and anti-inflammatory actions of rosmarinic acid.
Inhalation of rosemary essential oil has been shown in human studies to increase alertness and improve performance on attention-related tasks. The main volatile constituent 1,8-cineole, which is absorbed into the bloodstream via inhalation, is considered the primary active compound mediating these effects.
Rosemary oil has been tested in clinical trials against minoxidil for androgenetic alopecia and in RCTs assessing hair growth, thickness, and density. A 2015 randomized trial found topical rosemary oil comparable to 2% minoxidil for hair count at 6 months in male AGA. A 2025 RCT demonstrated rosemary-based oils significantly improved hair growth rate, thickness, density, and reduced hair fall vs. coconut oil control (p<0.0001).
Rosemary oil (Salvia rosmarinus, formerly Rosmarinus officinalis) has demonstrated hair-regrowth efficacy comparable to 2% minoxidil in a 6-month randomized controlled trial. It is thought to enhance scalp microcirculation and inhibit 5-alpha reductase via its active constituent carnosic acid, which promotes nerve growth factor-driven follicle recovery. A 2025 double-blind three-arm RCT further confirmed significant improvements in hair growth rate, thickness, density, and reduced hair fall.
Rosemary (Salvia rosmarinus/Rosmarinus officinalis) contains carnosic acid, carnosol, and rosmarinic acid — anti-aging compounds with potent Nrf2-activating, anti-inflammatory, and neuroprotective properties. A Japanese RCT of rosemary extract improved memory in older adults with cognitive impairment. Traditional Mediterranean use for longevity is well-documented.
Rosemary (Rosmarinus officinalis) is explicitly documented as an inducer of the hepatic glucuronidation pathway—a primary Phase II liver detoxification route for estrogen conjugation and clearance. It is listed alongside curcumin, resveratrol, and dandelion in formal reviews of Phase II liver detoxification-supporting nutrients. Its active compounds (carnosic acid, rosmarinic acid) are also Nrf2 activators.
Rosemary (Rosmarinus officinalis) and its active diterpenes carnosic acid and carnosol, along with rosmarinic acid, demonstrate hepatoprotective effects in preclinical studies through Nrf2 activation, antioxidant enzyme induction, and NF-κB inhibition. Animal studies show protection against CCl4 and APAP-induced liver injury. Traditional use as a liver tonic and cholagogue is documented in European herbal medicine.
Topical rosemary oil (Rosmarinus officinalis) enhances microcapillary perfusion and modulates prostaglandin E2 and leukotriene B4, prolonging the anagen phase. A randomized comparative trial (Panahi 2015, n=100) showed rosemary oil equaled 2% minoxidil in significant hair count increases at 6 months, with less scalp itching. A 2025 network meta-analysis confirmed topical rosemary as one of the best-evidenced non-conventional treatments for male AGA.
Both oral supplementation and aromatherapy with rosemary have shown memory benefits in human clinical trials. A crossover RCT in elderly adults found 750 mg of dried rosemary leaf improved speed of memory versus placebo. Inhaled rosemary essential oil enhanced overall memory quality and alertness in healthy adults. Oral rosemary also improved prospective and retrospective memory in a university student RCT.
Rosemary (Rosmarinus officinalis) has been associated with memory and alertness since ancient Greece, and modern science confirms that rosemary aroma and its constituent 1,8-cineole improve cognitive performance, alertness, and mood in RCTs.
A clinical trial in hemodialysis patients found topically applied rosemary oil significantly reduced musculoskeletal pain severity versus placebo. A study in rheumatoid arthritis patients receiving rosemary oil massage reported a 50% decrease in inflammatory knee pain over two weeks. Rosemary's analgesic and anti-inflammatory properties underlie these effects.
Oral rosemary-grapefruit polyphenol supplementation has been shown in a human clinical study to decrease wrinkle depth and improve skin elasticity after 12 weeks. In vitro evidence demonstrates rosemary diterpenes preserve collagen and elastin synthesis in UV-stressed human fibroblasts and inhibit matrix metalloproteinases MMP-1 and MMP-3.
A randomized clinical trial in university students found that 500 mg of rosemary taken orally twice daily for one month significantly improved sleep quality scores alongside anxiety and memory benefits. Aromatherapy with rosemary-lemon oil also improved sleep quality in elderly adults in a pre/post study.
A randomized, double-blind, placebo-controlled crossover trial found that four weeks of rosemary extract consumption significantly improved trait anxiety scores and heart rate variability, markers of chronic stress, in healthy adults. A single dose also reduced state anxiety acutely before a mental stressor. These effects are attributed to rosmarinic acid and diterpenes.
A placebo-controlled crossover human study found oral rosemary and grapefruit extract combination reduced UV-induced skin erythema from the first day of intake at both 100 mg and 200 mg doses. In vitro studies in human keratinocytes confirm rosemary diterpenes provide genoprotection against UVB-induced DNA damage and reduce ROS and inflammatory interleukins.
Rosemary is officially recognized by the EMA (European Medicines Agency) as a traditional herbal medicine for symptomatic relief of dyspepsia and mild spasmodic gastrointestinal disorders. The herb has a well-documented history of use for digestive complaints including flatulence, bloating, and intestinal spasms in European traditional medicine.
Rosemary (Rosmarinus officinalis) has been used in European herbal medicine for circulatory and cardiovascular support since antiquity. Its bioactives (carnosic acid, carnosol, rosmarinic acid) activate Nrf2, inhibit NF-κB, reduce LDL oxidation, and have anti-thrombotic effects relevant to arterial health. The scientific evidence derives primarily from in vitro and animal studies.
Rosemary has a deeply established traditional reputation for stimulating circulation, particularly to the head and periphery. It is classified as a circulatory stimulant in European herbal traditions and the PMC literature confirms its historical use for poor circulation. Topical use is recognized by the EMA for local stimulation of blood flow.
Rosemary (Rosmarinus officinalis) contains carnosic acid, carnosol, and rosmarinic acid, bioactive compounds with antioxidant and mild tyrosinase-inhibiting properties. It has traditional use as a topical skin-brightening herb in Mediterranean and European folk medicine, and its extracts appear in cosmeceutical formulations targeting periorbital hyperpigmentation for their antioxidant protective effects.
Rosemary is documented as a choleretic herb in folk medicine—meaning it increases bile secretion from the liver—which historically positions it as a digestive and gallbladder tonic. The EMA monograph explicitly notes that rosemary is contraindicated in gallbladder obstruction and gallstones, implying recognized activity on the biliary system.
Rosemary has a long history of traditional use for headaches in Mediterranean and European folk medicine. It is described as a cephalic herb that improves cerebral circulation, which has historically been considered the mechanism. No rigorous clinical trials specifically targeting headaches have been conducted.
Rosemary has traditional associations with heart health in European herbalism and demonstrates antithrombotic properties in human ex vivo testing. Its antioxidant and anti-inflammatory constituents may protect cardiovascular tissues from oxidative damage, though dedicated cardiac endpoint RCTs in humans are absent.
Rosemary (Rosmarinus officinalis/Salvia rosmarinus) is listed among herbs reported effective for dysmenorrhea and menstrual disorders in a PMC systematic review. Traditional European and Middle Eastern herbal medicine have used rosemary as an emmenagogue and antispasmodic for menstrual pain. Its rosmarinic acid, carnosic acid, and flavonoid content provide anti-inflammatory properties.
Rosemary (Rosmarinus officinalis) has been used in European traditional medicine since antiquity for nervous system stimulation, cognitive enhancement, and headache relief. Modern research identifies rosmarinic acid and carnosic acid as active compounds with neuroprotective and acetylcholinesterase-inhibiting properties.
Rosemary has traditional use for nerve pain, including sciatica, and its bioactives show antinociceptive effects in preclinical neuropathic pain models. Animal studies specifically demonstrate protection against diabetic neuropathy and pain relief in neuropathy models, but human clinical trial evidence in neuropathy populations specifically is lacking.
Rosemary has documented traditional use for pain along the sciatic nerve in European folk medicine and is listed among its traditional indications in pharmaceutical references. No human clinical trials specifically in sciatica have been conducted.
Rosemary (Rosmarinus officinalis) has been used in traditional European herbal medicine for wound healing, antisepsis, and skin health. Its active compounds—carnosic acid, carnosol, rosmarinic acid—have anti-inflammatory and antimicrobial properties. Preclinical evidence supports its wound-healing activity, but clinical RCT data are limited.
Volver